NCT06380699View on ClinicalTrials.gov

Study to Assess PK, Safety and Tolerability in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

November 16, 2023

Study Completion Date

December 25, 2023

Conditions
Acute Ischemic Stroke
Interventions
DRUG

QHRD106 Injection

PEG-tissue kallikrein-1

DRUG

Human Urinary Kallidinogenase

tissue kallikrein-1

DRUG

placebo

placebo

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

Sponsors
All Listed Sponsors
lead

Changzhou Qianhong Bio-pharma Co., Ltd.

INDUSTRY

NCT06380699 - Study to Assess PK, Safety and Tolerability in Healthy Subjects | Biotech Hunter | Biotech Hunter